Minerva Neurosciences Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
NERV
- Investments
-
2
- Share Price
-
$2.30
- (As of Friday Closing)
Minerva Neurosciences General Information
Description
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Contact Information
Website
www.minervaneurosciences.comCorporate Office
- 1500 District Avenue
- Burlington, MA 01803
- United States
Corporate Office
- 1500 District Avenue
- Burlington, MA 01803
- United States
Minerva Neurosciences Timeline
Minerva Neurosciences Stock Performance
As of 13-Nov-2026, Minerva Neurosciences’s stock price is $2.30. Its current market cap is $115M with 49.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.30 | $2.38 | $1.96 - $8.80 | $115M | 49.8M | 196K | -$25.66 |
Minerva Neurosciences Financials Summary
As of 30-Sep-2026, Minerva Neurosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 96,428 | 161,676 | (10,992) | (3,895) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (290,858) | (293,418) | 6,024 | (21,691) |
| Net Income | (290,859) | (293,423) | 1,439 | (30,005) |
| Total Assets | 98,278 | 97,969 | 37,144 | 56,900 |
| Total Debt | 0 | 0 | 0 | 0 |
Minerva Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Minerva Neurosciences Comparisons
Industry
Financing
Details
Minerva Neurosciences Competitors (88)
One of Minerva Neurosciences’s 88 competitors is Intracellular Therapies, a Formerly VC-backed company based in Bedminster, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intracellular Therapies | Formerly VC-backed | Bedminster, NJ | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Minerva Neurosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Minerva Neurosciences Patents
Minerva Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4798200-A1 | Roluperidone for the treatment of lysosomal storage disorders and their symptoms | Pending | 24-Oct-2023 | ||
| WO-2025090588-A1 | Roluperidone for the treatment of lysosomal storage disorders and their symptoms | Inactive | 24-Oct-2023 | ||
| US-20260232653-A1 | Use of condensed azacycle compounds for the treatment of lysosomal storage disorders | Pending | 16-Feb-2023 | ||
| WO-2024173727-A2 | Use of condensed azacycle compounds for the treatment of lysosomal storage disorders | Inactive | 16-Feb-2023 | ||
| WO-2024173727-A3 | Use of condensed azacycle compounds for the treatment of lysosomal storage disorders | Inactive | 16-Feb-2023 | A61K31/496 |
Minerva Neurosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Minerva Neurosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Minerva Neurosciences Acquisitions (2)
Minerva Neurosciences’s most recent deal was a Merger/Acquisition with Mind-NRG for . The deal was made on 11-Feb-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Mind-NRG | 11-Feb-2014 | Merger/Acquisition | Drug Discovery | ||
| Sonkei Pharmaceuticals | 12-Nov-2013 | Merger of Equals | Drug Discovery |
Minerva Neurosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.56 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Minerva Neurosciences FAQs
-
When was Minerva Neurosciences founded?
Minerva Neurosciences was founded in 2007.
-
Where is Minerva Neurosciences headquartered?
Minerva Neurosciences is headquartered in Burlington, MA.
-
What is the size of Minerva Neurosciences?
Minerva Neurosciences has 7 total employees.
-
What industry is Minerva Neurosciences in?
Minerva Neurosciences’s primary industry is Drug Discovery.
-
Is Minerva Neurosciences a private or public company?
Minerva Neurosciences is a Public company.
-
What is Minerva Neurosciences’s stock symbol?
The ticker symbol for Minerva Neurosciences is NERV.
-
What is the current stock price of Minerva Neurosciences?
As of 13-Nov-2026 the stock price of Minerva Neurosciences is $2.30.
-
What is the current market cap of Minerva Neurosciences?
The current market capitalization of Minerva Neurosciences is $115M.
-
Who are Minerva Neurosciences’s competitors?
Intracellular Therapies, Ardelyx, Marinus Pharmaceuticals, Vertex Pharmaceuticals, and Immunocore Holdings are some of the 88 competitors of Minerva Neurosciences.
-
What is Minerva Neurosciences’s annual earnings per share (EPS)?
Minerva Neurosciences’s EPS for 12 months was -$25.66.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
